Table 3.
Physical and chemical properties of most frequently used therapeutic radionuclides for targeted radionuclide therapy of ovarian cancer.
| electron-emitters | α-emitters | |||||
|---|---|---|---|---|---|---|
| Radionuclide | 177Lu | 161Tb | 225Ac | 211At | 212Pb | |
| (and daughters) | (221Fr/ 217At/ 213Bi) | (211Po/ 207Bi) | (212Bi/ 212Po/ 208TI) | |||
| Tp (d) | 6.64 | 6.95 | 9.92 | 0.3 | 0.44 | |
| Decay mode (%) | β- (100) | β- (100) | α (100) | ε (58.2) & α (41.8) | β- (100) | |
| (and daughters) | α (100)/ α (99.99)/ | α (100)/ ε (100) | β- (64.06) & α (35.94) / α (64.05) | |||
| β- (97.8) & α (2.2) | β- (35.94) | |||||
| Principal Eβ/α, keV (%) | 148.8 (79.4) | 157.4 (65) | 225Ac: 5830 (50.7) | 211At: IC: 78.5 (47) & AE: 8.5 (105) | 212Pb: 93.28 (81.5) & IC: 148.1 (31.0) | |
| AE: 6.2 (8.6) | AE: 5.2 (87.9) | 221Fr: 6341.0 (83.3) | 211Po: 7450 (98.9) | 212Bi: 6340 (35) & 6300 (26) | ||
| IC: 101.7 (6.8) | IC: 39.9 (42.4) & 16.6 (41) | 217At: 7066.9 (99.9) | 212Po: 10180 (42) | |||
| 213Bi: 491.8 (66.8) | 208TI: 649.5 (49.1) & 441.5 (24.2) | |||||
| Principal Eγ/XR, keV (%) | 208 (11) | 25.6 (23.2) | 221Fr: 218.0 (11.4) | 211At: 81.5 (29) & 78.9 (18) | 212Pb: 238.6 (43.6) & 77.1 (16.4) | |
| 113 (6.6) | 48.9 (17.7) | 213Bi: 440.5 (25.9) | 208TI: 583.2 (85.0) & 510.8 (22.6) | |||
| 74.6 (10.3) | ||||||
| Principle particle range in tissue (µm) | 280 (β-) | 301 (β-), 13 (IC), 0.1 (AE) | 225Ac: 47 (α) | 60 (α) | 212Po: 50.1 (α) | |
| 213Bi/213Po: 85 (α) | 212Bi: 91.0 (α) | |||||
| Oxidation state | 3+ | 3+ | 3+ | 1-/ 1+ * | 2+ | |
| Conventional chelator(s) | DOTA/CHX-A"-DTPA | DOTA/DOTAGA | DOTA/Macropa | NA; astatoaryl compounds | DOTA/TCMC | |
| Theranostic pair | 111In/ 68Ga/ 89Zr/ 64Cu | 152Tb/ 155Tb | 111In/ 68Ga/ 226Ac/ 132La/ 133La | 209At/ 131I/ 124I | 203Pb | |